Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGENNASDAQ:EXOZNASDAQ:LYELOTCMKTS:MRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.45-1.4%$1.41$1.13▼$2.66$129.39M2.61370,607 shs173,553 shsEXOZExozymes$14.90+2.1%$12.10$8.50▼$23.99$124.68MN/A18,895 shs2,590 shsLYELLyell Immunopharma$0.42-1.0%$0.46$0.39▼$2.85$123.48M-0.251.04 million shs527,077 shsMRMDMariMed$0.07-4.1%$0.09$0.07▼$0.29$28.77M3.15413,416 shs741,349 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen0.00%+4.32%-2.03%-31.15%-38.03%EXOZExozymes0.00%-0.93%+23.65%-15.87%+1,489,999,900.00%LYELLyell Immunopharma0.00%+0.75%-10.47%-40.33%-84.85%MRMDMariMed0.00%-7.27%-28.36%-45.19%-69.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGENCompugen1.7679 of 5 stars3.54.00.00.01.90.00.0EXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/ALYELLyell Immunopharma2.9266 of 5 stars2.82.00.00.02.85.01.3MRMDMariMed0.8198 of 5 stars0.05.00.00.01.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 3.00Buy$4.00175.86% UpsideEXOZExozymes 0.00N/AN/AN/ALYELLyell Immunopharma 1.50Reduce$1.00139.18% UpsideMRMDMariMed 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest MRMD, EXOZ, CGEN, and LYEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/3/2025MRMDMariMedNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/13/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$27.59M4.69N/AN/A$0.73 per share1.99EXOZExozymesN/AN/AN/AN/AN/AN/ALYELLyell Immunopharma$65K1,899.70N/AN/A$2.60 per share0.16MRMDMariMed$148.60M0.19$0.01 per share5.59$0.19 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen-$18.75M-$0.1672.50N/AN/A2.67%2.62%1.36%8/5/2025 (Estimated)EXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/ALYELLyell Immunopharma-$234.63M-$1.25N/AN/AN/A-323,792.09%-34.64%-30.02%8/6/2025 (Estimated)MRMDMariMed-$16.03M-$0.03N/A∞N/A-10.97%-2.75%-1.06%8/6/2025 (Estimated)Latest MRMD, EXOZ, CGEN, and LYEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/13/2025Q1 2025LYELLyell Immunopharma-$0.19-$0.18+$0.01-$0.18N/A$0.01 million5/12/2025Q1 2025EXOZExozymesN/A-$0.22N/A-$0.22N/AN/A5/7/2025Q1 2025MRMDMariMed-$0.01-$0.01N/A-$0.01$38.33 million$37.96 million3/12/2025Q4 2024LYELLyell Immunopharma-$0.20-$0.72-$0.52-$0.72N/A$0.01 million3/5/2025Q4 2024MRMDMariMed-$0.01-$0.01N/A-$0.02$42.00 million$39.00 million3/4/2025Q4 2024CGENCompugen$0.07-$0.07-$0.14-$0.07$17.47 million$1.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/AMRMDMariMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A4.144.14EXOZExozymesN/AN/AN/ALYELLyell ImmunopharmaN/A13.4313.43MRMDMariMed1.011.550.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%EXOZExozymesN/ALYELLyell Immunopharma66.05%MRMDMariMed0.18%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%EXOZExozymesN/ALYELLyell Immunopharma25.10%MRMDMariMed18.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7089.24 million80.76 millionOptionableEXOZExozymes298.37 millionN/AN/ALYELLyell Immunopharma270295.34 million218.83 millionOptionableMRMDMariMed260388.71 million301.65 millionNot OptionableMRMD, EXOZ, CGEN, and LYEL HeadlinesRecent News About These CompaniesNoble Financial Has Weak Outlook for MariMed FY2025 EarningsMay 15, 2025 | americanbankingnews.comWhat is Noble Financial's Forecast for MariMed Q2 Earnings?May 15, 2025 | americanbankingnews.comMariMed Inc.: MariMed Reports First Quarter 2025 EarningsMay 8, 2025 | finanznachrichten.deMariMed Inc. (MRMD) Reports Q1 Loss, Lags Revenue EstimatesMay 7, 2025 | zacks.comMariMed Reports First Quarter 2025 EarningsMay 7, 2025 | globenewswire.comMariMed Announces First Quarter 2025 Earnings DateApril 8, 2025 | globenewswire.comMariMed Promotes Ryan Crandall to Chief Commercial OfficerApril 7, 2025 | globenewswire.comMariMed's Betty's Eddies Expands Top-Selling Brand With Introduction of THC & CBG-Infused Caramel ChewsApril 3, 2025 | globenewswire.comMarimed launches Nature’s Heritage Flower in IllinoisApril 1, 2025 | markets.businessinsider.comMariMed Launches Nature's Heritage™ Flower in IllinoisApril 1, 2025 | globenewswire.comMariMed Inc. (PNK:MRMD) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comMariMed Reports Record Revenue Amid Strategic GrowthMarch 6, 2025 | tipranks.comMariMed has price target chopped at VentumMarch 6, 2025 | cantechletter.comMariMed Inc. (MRMD) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comMariMed Reports Fourth Quarter and Full Year 2024 EarningsMarch 5, 2025 | globenewswire.comMariMed Completes Acquisition of First State Compassion, Strengthening Market Position in DelawareMarch 3, 2025 | globenewswire.comMariMed Announces Fourth Quarter and Full Year 2024 Earnings DateFebruary 11, 2025 | globenewswire.comMariMed Commences Wholesale Operations in MissouriDecember 23, 2024 | globenewswire.comMariMed Reports Third Quarter 2024 EarningsNovember 6, 2024 | globenewswire.comInHouse by MariMed Launches Help on the Homefront, to Support Veterans Facing Housing ChallengesOctober 31, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRMD, EXOZ, CGEN, and LYEL Company DescriptionsCompugen NASDAQ:CGEN$1.45 -0.02 (-1.36%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.42 -0.03 (-2.41%) As of 05/23/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Exozymes NASDAQ:EXOZ$14.90 +0.30 (+2.05%) As of 05/23/2025 03:57 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Lyell Immunopharma NASDAQ:LYEL$0.42 0.00 (-1.02%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.41 -0.01 (-1.46%) As of 05/23/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.MariMed OTCMKTS:MRMD$0.07 0.00 (-4.15%) As of 05/23/2025 03:56 PM EasternMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
